The short version of synaptic plasticity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-20. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Actin was first observed experimentally in 1887 by W.D. Halliburton, who extracted a protein from muscle that 'coagulated' preparations of myosin that he called "myosin-ferment". However, Halliburton was unable to further refine his findings, and the discovery of actin is credited instead to Brunó Ferenc Straub, a young biochemist working in Albert Szent-Györgyi's laboratory at the Institute of Medical Chemistry at the University of Szeged, Hungary. Following up on the discovery of Ilona Banga & Szent-Györgyi in 1941 that the coagulation only occurs in some myosin extractions and was reversed upon the addition of ATP, Straub identified and purified actin from those myosin preparations that did coagulate. Building on Banga's original extraction method, he developed a novel technique for extracting muscle protein that allowed him to isolate substantial amounts of relatively pure actin, published in 1942. Straub's method is essentially the same as that used in laboratories today. Since Straub's protein was necessary to activate the coagulation of myosin, it was dubbed actin. Realizing that Banga's coagulating myosin preparations contained actin as well, Szent-Györgyi called the mixture of both proteins actomyosin. The hostilities of World War II meant Szent-Gyorgyi was unable to publish his lab's work in Western scientific journals. Actin therefore only became well known in the West in 1945, when their paper was published as a supplement to the Acta Physiologica Scandinavica.
== Natural occurrences == Hydroquinones are one of the two primary reagents in the defensive glands of bombardier beetles, along with hydrogen peroxide (and perhaps other compounds, depending on the species), which collect in a reservoir. The reservoir opens through a muscle-controlled valve onto a thick-walled reaction chamber. This chamber is lined with cells that secrete catalases and peroxidases. When the contents of the reservoir are forced into the reaction chamber, the catalases and peroxidases rapidly break down the hydrogen peroxide and catalyze the oxidation of the hydroquinones into p-quinones. These reactions release free oxygen and generate enough heat to bring the mixture to the boiling point and vaporize about a fifth of it, producing a hot spray from the beetle's abdomen. Hydroquinone is thought to be the active toxin in Agaricus hondensis mushrooms. Hydroquinone is one of the chemical constituents of the natural product propolis. It is also one of the chemical compounds found in castoreum. This compound is gathered from the beaver's castor sacs.
Roberts (2001) presented a spectrum of responses to be expected under a variety of flux rate conditions varying from very slow seepage to rapid venting. Very-slow-seepage sites do not support complex chemosynthetic communities; rather, they usually only support simple microbial mats (Beggiatoa sp.). In the upper slope environment, the hard substrates resulting from carbonate precipitation can have associated communities of non-chemosynthetic animals, including a variety of sessile cnidarians such as corals and sea anemones. At the rapid flux end of the spectrum, fluidized sediment generally accompanies hydrocarbons and formation fluids arriving at the seafloor. Mud volcanoes and mud flows result. Somewhere between these two end members exists the conditions that support densely populated and diverse communities of chemosynthetic organisms (microbial mats, siboglinid tube worms, bathymodioline mussels, lucinid and vesicomyid clams, and associated organisms). These areas are frequently associated with surface or near-surface gas hydrate deposits. They also have localized areas of lithified seafloor, generally authigenic carbonates but sometimes more exotic minerals such as barite are present.
Sources: en.wikipedia.org
==== Deficit in consolidation of memory traces ==== α-CaMKII heterozygous mice express half the normal protein level as the wild-type level. These mice showed normal memory storage in the hippocampus, but deficits in consolidation of memory in the cortex.
=== Light properties === Switch on time: LEDs light up extremely quickly. A typical red indicator LED achieves full brightness in under a microsecond. LEDs used in communications devices can have even faster response times. Focus: The solid package of the LED can be designed to focus its light. Incandescent and fluorescent sources often require an external reflector to collect light and direct it in a usable manner. For larger LED packages total internal reflection (TIR) lenses are often used to the same effect. When large quantities of light are needed, many light sources such as LED chips are usually deployed, which are difficult to focus or collimate on the same target. Area light source: Single LEDs do not approximate a point source of light giving a spherical light distribution, but rather a lambertian distribution. So, LEDs are difficult to apply to uses needing a spherical light field. Different fields of light can be manipulated by the application of different optics or "lenses". LEDs cannot provide divergence below a few degrees.
Chair, Financial Reporting Advisory Board. For Public Service. Diana Marjorie Parkes. Co-Founder and Patron, The Joanna Simpson Foundation. For services to Vulnerable Children Suffering from Domestic Abuse and Domestic Homicide. William James Pease-Watkin (Bill Watkin). Chief Executive, Sixth Form Colleges Association. For services to Further Education. Professor Andrew David Mark Pettegree, FBA. Historian and Author. For services to Literature. Andrew Kerry Pike, OBE. Lately Director, GREAT Britain and Northern Ireland Campaign, Cabinet Office. For Public Service. Erin Pizzey. Campaigner and Activist. For services to the Victims of Domestic Abuse. Professor Ann Prentice, OBE. Honorary Senior Visiting Fellow, MRC Epidemiology Unit, University of Cambridge. For services to British and Global Public Health Nutrition. Jessica Mary Pulay. Co-Head of Policy and Markets, UK Debt Management Office. For services to Public Finances. Professor Margaret Mary Rae. Lately President, UK Faculty of Public Health. For services to Public Health and to Public Health Standards. Dr. Mala Rao, OBE. Senior Clinical Fellow, Imperial College London. For services to Public Health, the NHS, and to Equality and Diversity. Mark Julian Read. Chief Executive Officer, WPP. For services to the Creative Industries. Simon Trevor Regis. Deputy Director, Department for Culture, Media and Sport Legal Advisers, Government Legal Department. For services to Legislation. Professor Elizabeth Jane Robertson. Professor of Developmental Biology, University of Oxford. For services to Medical Sciences.
Few labs are subject to complaints. For 2024, CLIA budgeted for approximately 209 onsite complaint surveys, representing ~0.06% of the 320,000 CLIA labs. The low volume of lab complaints may be related to complainants' concerns about anonymity and fear of retaliation for filing a complaint. It may be easy for a lab to determine the source of a complaint filed by a lab worker. For example, in some cases, either the nature of the complaint or the piece of testing equipment in question could narrow the list of possible complainants. Because of the difficulty of protecting the anonymity of lab workers who file complaints, whistle-blower protections for such individuals are particularly important. Following congressional testimony by a Maryland hospital lab worker that she and her colleagues feared losing their jobs because of the complaints, a whistleblower protection bill, the "Clinical Laboratory Compliance Improvement Act of 2005", was introduced, but died in committee. CLIA and federal law provide no specific whistleblower protection to laboratory employees who report CLIA violations. However, CLIA complaints made under the False Claims Act (FCA) may be afforded whistleblower protections. The FCA, which prohibits fraud against government programs, including Medicare and Medicaid, may cover CLIA violations that give rise to FCA violations, such as laboratory deficiencies that render billed services medically worthless. Whether CLIA compliance is a condition of Medicare payment is a contested issue.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.